ArticleClinical & experimental metastasis2005
Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer.
Article in Clinical & experimental metastasis, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges.Molecular pharmaceutics · 2021Review
- Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?International journal of molecular sciences · 2021Review
- Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma: A Review of the Current Status of Literature.Cancers · 2020Review
- B7-H3-targeted Radioimmunotherapy of Human Cancer.Current medicinal chemistry · 2020Review
- Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy.Cancer letters · 2019Review
- Article
- In vitro models of cancer stem cells and clinical applications.BMC cancer · 2016Review
- Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.Expert opinion on biological therapy · 2016Review
- Antitumoral materials with regenerative function obtained using a layer-by-layer technique.Drug design, development and therapy · 2015Article
- Fibroblast heterogeneity in the cancer wound.The Journal of experimental medicine · 2014Review
- Targeted alpha anticancer therapies: update and future prospects.Biologics : targets & therapy · 2014Review
- Systemic targeted alpha radiotherapy for cancer.Journal of biomedical physics & engineering · 2013Review
- Article
- The therapeutic value of monoclonal antibodies directed against immunogenic tumor glycoproteins.Journal of Cancer · 2010Article
- Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy?Seminars in cell & developmental biology · 2010Review
- Cancer associated fibroblasts (CAFs) in tumor microenvironment.Frontiers in bioscience (Landmark edition) · 2010Review
- The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity.BMC biotechnology · 2009Article
- Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer.European journal of nuclear medicine and molecular imaging · 2008Article
- Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.Bioconjugate chemistry · 2008Article
- Anti-cancer therapies targeting the tumor stroma.Cancer immunology, immunotherapy : CII · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe urokinase plasminogen activator (uPA) and its receptor (uPAR) are expressed by pancreatic cancer cells and can be targeted by the plasminogen activator inhibitor type 2 (PAI2). We have labeled PAI2 with (213)Bi to form the alpha conjugate (AC), and have studied its in vitro cytotoxicity and in vivo efficacy. METHODS AND MATERIALS: The expression of uPA/uPAR on pancreatic cell lines, human pancreatic cancer tissues, lymph node metastases, and mouse xenografts were detected by immunohistochemistry, confocal microscopy, and flow cytometry. Cytotoxicity was assessed by the MTS and TUNEL assay. At 2 days post-cancer cell subcutaneous inoculation, mice were injected with AC by local or systemic injection.
resultsuPA/uPAR is strongly expressed on pancreatic cancer cell lines and cancer tissues. The AC can target and kill cancer cells in vitro in a concentration-dependent fashion. Some 90% of TUNEL positive cells were found after incubation with 1.2 MBq/ml of AC. A single local injection of approximately 222 MBq/kg 2 days post-cell inoculation can completely inhibit tumor growth over 12 weeks, and an intraperitoneal injection of 111 MBq/kg causes significant tumor growth delay.
conclusions(213)Bi-PAI2 can specifically target pancreatic cancer cells in vitro and inhibit tumor growth in vivo. (213)Bi-PAI2 may be a useful agent for the treatment of post-surgical pancreatic cancer patients with minimum residual disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.